drugset
Drugs / TB31F
last change Jan 2026 re-read 3 minutes ago

TB31F

Monoclonal antibody

Developed for
Plasmodium falciparum malaria
Investigated by
Radboud University Medical Center · London School of Hygiene and Tropical Medicine · Malaria Research and Training Center, Bamako, Mali · The PATH Malaria Vaccine Initiative (MVI)

Trials 2

today NCT06413108 · Ph 1/2 NCT04238689 · Ph 1
2020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT04238689 Feb 2020 → Mar 2021 Plasmodium falciparum malaria Radboud University Medical Center Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT06413108 Jul 2024 → Jan 2026 Plasmodium falciparum malaria Radboud University Medical Center Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as TB31F ClinicalTrials.gov intervention name — accepted as the source's own label NCT06413108 ↗
1

NCT04238689 ↗
Action Inhibit “TB31F is a humanised monoclonal antibody that binds the gamete surface protein Pfs48/45 and inhibits fertilisation” PMID 35963275 ↗ Aug 2022
Modality Monoclonal antibody “TB31F is a humanised monoclonal antibody” PMID 35963275 ↗ Aug 2022
Route Intravenous “participants were administered a single intravenous dose of 0·1, 1, 3, or 10 mg/kg TB31F or a subcutaneous dose of 100 mg TB31F” PMID 35963275 ↗ Aug 2022
Route Subcutaneous “participants were administered a single intravenous dose of 0·1, 1, 3, or 10 mg/kg TB31F or a subcutaneous dose of 100 mg TB31F” PMID 35963275 ↗ Aug 2022